Tutorials
Gilead Sciences Inc logo

Gilead Sciences Inc

MXN 1247.00 (+0.56%) Aug 12
On watch
P/E:
19.20
P/B:
3.90
Market Cap:
MXN 1.58T ($ 79.45B)
Enterprise V:
MXN 1.99T ($ 100.14B)
Volume:
1.14K
Avg Vol (2M):
2.27K
Also Trade In:
Volume:
1.14K
Market Cap MXN:
1.58T
Market Cap $:
79.45B
PE Ratio:
19.20
Avg Vol (2-Month):
2.27K
Enterprise Value MXN:
1.99T
Enterprise Value $:
100.14B
PB Ratio:
3.90
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Gilead Sciences Inc
NAICS : 325412 SIC : 2834
333 Lakeside Drive, Foster, CA, USA, 94404
Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Financials (Next Earnings Date:2022-10-28 Est.)

MEX:GILD's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil MXN) 561,000.874
EPS (TTM) (MXN) 65.993
Beta -0.7
Volatility % 22.55
14-Day RSI 48.49
14-Day ATR (MXN) 12.682067
20-Day SMA (MXN) 1252.5855
12-1 Month Momentum % -8.38
52-Week Range (MXN) 1160 - 1554.99
Shares Outstanding (Mil) 1,253.37

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Gilead Sciences Inc Filings

Document Form Filing Date
No Filing Data